Status:
COMPLETED
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
Lead Sponsor:
Duke University
Conditions:
Venous Thromboembolism
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.
Detailed Description
Subjects who are receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer, including primaries of mullerian, peritoneal, or fallopian tube origin, with a Khorana score of 1 will be re...
Eligibility Criteria
Inclusion
- Khorana score = 1
- Over age 18
- English-speaking female patients
- Able to consent
- Receiving neoadjuvant chemotherapy Cancer of primary ovarian, fallopian tube, mullerian, or peritoneal origin
Exclusion
- Allergy or intolerance to study medication
- Indication for a non-aspirin form of antiplatelet (i.e. cardiac stent)
- Already on alternative form of anticoagulation
- Active bleeding
- High risk for active bleeding (i.e. recent intracranial bleed or gastrointestinal bleed, known brain metastases)
- Thrombocytopenia (platelets \<50,000)
- Unable to complete medication adherence diary
- Unable to take oral medications
Key Trial Info
Start Date :
August 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 2 2022
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04352439
Start Date
August 8 2020
End Date
March 2 2022
Last Update
September 26 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sarasota Memorial HealthCare System
Sarasota, Florida, United States, 34329
2
Duke University Hospital
Durham, North Carolina, United States, 27710